The FDA should immediately reinstate the in-person dispensing requirement for mifepristone

Evolving US policy battles over drug pricing and healthcare affordability, tracking legislation, court rulings, regulatory actions, and industry responses shaping costs, access, and market dynamics.

Food and Drug Administration officials said in a court filing disclosed October 7, 2026, that their safety review of mifepristone would not be completed until March. The agency will continue evaluating the abortion drug, extending a review central to its distribution rules.